Faron Pharmaceuticals Oy, a clinical-stage biopharmaceutical company, is set to release its unaudited half-year financial results for the six months ended June 30, 2024, on Tuesday, 27 August 2024. The company will also host a live hybrid briefing and Q&A session for investors, analysts, and media on Wednesday, 28 August 2024, featuring Dr. Juho Jalkanen, Chief Executive Officer, and Yrj Wichmann, Chief Financial Officer.

The BEXMAB study, an open-label Phase 1/2 clinical trial, is investigating bexmarilimab in combination with standard of care (SoC) in aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Bexmarilimab, Faron's investigational immunotherapy, is designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function and igniting the immune system. It binds to Clever-1, an immunosuppressive receptor found on macrophages, altering the tumor microenvironment and reprogramming macrophages to an immunostimulatory state.

Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies. Its lead asset, bexmarilimab, is a novel anti-Clever-1 humanized antibody with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. The company's mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.

The announcement also includes forward-looking statements, reflecting the company's current beliefs and assumptions based on the Directors' expectations regarding the company's future growth, results of operations, performance, and business prospects. For more information, interested parties can visit the company's website or contact the provided investor and media contacts.